Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1410-1414

  Lindgren, P ^a   Borgstrom F ^a   Stalhammar J ^b   Alemao, E ^c   Jonsson L ^d  

^a European Health Economics   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d European Health Economics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447324067     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01468.x     Document Type: Article

References (18)

1. Wilhelmsen L, Johansson S, Rosengren A et al. Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J Intern Med 1997 242 : 199 211.
2. Lindgren P, Borgström F, Stålhammar J et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005 12 : 530 4.
3. Wood D, De Backer G, Færgeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998 140 : 199 270.
4. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003 10 : S1 78.
5. Pearson TA, Denke MA, McBride PE et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005 80 : 587 95.
6. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002 89 : 672 8.
7. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin vs. gemfibrozil + any statin. Am J Cardiol 2005 95 : 120 2.
8. Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004 147 : 705 13.
9. Thiebaud P, Patel BV, Nichol MB et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005 11 : 670 4.
10. Van Ganse E, Laforest L, Alemao E et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005 21 : 1389 99.
11. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001 357 : 995 1001.
12. Ose L, Skjeldestad FE, Bakken IJ et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006 6 : 121 8.
13. Leander K, Hallqvist J, Reuterwall C et al. Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: results from the Stockholm Heart Epidemiology Program (SHEEP). Epidemiology 2001 12 : 215 21.
14. Strandberg TE, Lehto S, Pyorala K et al. Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J 1997 18 : 1725 7.
15. Alfredsson K, Hammar N, Gillstrom P. Increasing differences in myocardial infarction incidence between socio-economic groups in Stockholm. Nutr Metab Cardiovasc Dis 1995 5 : 99 104.
16. Benner JS, Tierce JC, Ballantyne CM et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004 22 (Suppl. 3 13 23.
17. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 93.
18. Staenk EJ, Sarawate C, Wiley VJ et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007 23 : 553 63.